Cardlytics Completes Sale of Bridg Assets to PAR Technology for 1.81 Million PAR Shares

CollPlant Biotechnologies, a regenerative and aesthetic medicine company, received a notice from Nasdaq that its ordinary shares have been below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has been granted a 180-day compliance period to regain compliance with the minimum bid price requirement, which it intends to monitor and address during this period.